The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The ...

Board-certified subspecialists in the Division of Pediatric Allergy, Asthma and Immunology specialize in the diagnosis and treatment of children with allergic and immunologic diseases. Allergic ...

Please provide your email address to receive an email when new articles are posted on . Children with growth hormone deficiency assigned long-acting recombinant GH therapy experienced an increase in ...

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...